Shiyu Mao Junfeng Zhang Yadong Guo Ziwei Zhang Yuan Wu Wentao Zhang Longsheng Wang Jiang Geng Yang Yan Xudong Yao
10.2147/DDDT.S181122
Drug Des Devel Ther
2019 Jan 11;13:291-300.
mdm2 hyperprogression immune checkpoint blockade programmed cell death ligand-1 urothelial bladder carcinoma
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/30666091/
Antineoplastic Agents / therapeutic use B7-H1 Antigen / metabolism Cisplatin / therapeutic use Urinary Bladder Neoplasms / therapy
Antineoplastic Agents / therapeutic use B7-H1 Antigen / metabolism Cisplatin / therapeutic use Urinary Bladder Neoplasms / therapy Case Reports Administration, Intravesical Antineoplastic Agents / administration & dosage Cisplatin / administration & dosage Humans Immunotherapy Male Middle Aged Urinary Bladder Neoplasms / metabolism Urinary Bladder Neoplasms / secondary Antineoplastic Agents B7-H1 Antigen Cisplatin
PMC6333318
30666091
Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
2019